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MEDICATION ADHERENCE STUDIES
MA1
IMpACT Of A pHARMACIST MEDICATION ADHERENCE CONSUlTATION 
pROgRAM ON HEAlTH CARE COSTS AND RISk Of HOSpITAlIzATION
Wade R.L.1, Hill J.W.1, Akinbosoye O.2, Jiang Z.2, Mu Y.2, Sun K.1, Karkare S3, Taitel M.S.2
1IMS Health, Plymouth Meeting, PA, USA, 2Walgreen Co., Deerfield, IL, USA, 3IMS Health, 
Deerfield, IL, USA
Objectives: Non-adherence is associated with poorer health outcomes and 
increased costs. This study evaluated the impact of a community pharmacist 
medication adherence consultation on health care costs and the risk of hospitali-
zation. MethOds: Patients initiating therapy within 16 drug classes were offered 
face-to-face or telephonic consultations by a Walgreens pharmacist between 
2/7/2013 – 10/6/2013. Consultation included motivational interviewing focused on 
fitting medication-taking behavior into patients’ daily routine, and removing bar-
riers to adherence. Patients were assigned to two groups according to the intensity 
of consultation: no consultations (NC) and ≥ 1 consultations received (CR). Patients 
were linked deterministically to the IMS Health PharMetrics Plus database such that 
6 months of pharmacy and medical claims data pre and post their index date could 
be analyzed. Cost differences from the pre to post-index periods were compared 
between NC and CR groups, using difference in differences estimation in a GLM 
model, controlling for demographic and clinical confounders. Results: CR patients 
(n= 58,449) and NC patients (n= 53,870) had similar age (48.2 vs. 47.7 years), gender 
(59.0% vs. 57.7% female) and disease burden (0.61 vs. 0.58 for Charlson Comorbidity 
Index, CCI). CR patients incurred significantly lower pre- to post-index GLM-adjusted 
total health care costs (-$266/-4.3% lower, p= 0.001), comprised of lower inpatient 
(-$231, p= 0.009), lower pharmacy (-$43, p< 0.0001), and similar outpatient costs (-$36, 
p= 0.279); and had a lower probability of hospitalization (OR: 0.92, 95% CI: 0.86, 0.98, 
p= 0.009). CR patients with a CCI equal to 1-2 realized the greatest cost savings 
(-$688, p= 0.001) compared to patients with CCI= 0 (-$106, p= 0.051), and CCI≥ 3 ($575, 
p= 0.293). cOnclusiOns: Patients receiving structured pharmacist consultations 
focused on improving medication adherence were shown to have significantly lower 
health care costs and risk of hospitalization. Ongoing studies will explore underly-
ing relationships between program participation, adherence, and impact on health 
outcomes and costs.
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Barcelona, Spain
Objectives: We have previously demonstrated that full adherence with ACE-
Inhibitors (ACEI) or statins in a post-myocardial infarction (MI) population is 
associated with lower rate of cardiovascular (CV) events compared to partial- or 
non-adherence. Herein, we sought to determine the direct medical costs attributable 
to partial- and non- adherence to these therapies. MethOds: Data on CV events 
and resource utilization were collected through a retrospective, nested cohort study 
in a large US insurer database. We also analyzed two national files for physician 
and non-physician unit cost weighted averages of CV events (stroke, MI, athero-
sclerosis or angina), procedures (revascularization and CV tests) and visits (emer-
gency room and outpatient CV visits). We estimated per person cost differences 
between adherence groups and the sensitivity of the Results using weighted and 
unweighted averages. A third-party payer economic perspective was adopted; all 
costs were expressed in 2014$. Results: The estimated per patient weighted aver-
age annual cumulative medical costs were $5,153 for adherent, $6,470 for partially-
adherent and $6,767 for non-adherent patients. This difference was mainly driven 
by a lower rate of CV events and revascularizations for adherent patients. Applying 
referenced unweighted averages, we estimated that the MI reference unit cost was 
$4,325 higher than the weighted average cost (p< 0.001); the CV test unit cost was 
$1,010 higher than the weighted average cost (p= 0.001). Using national prevalence 
data for incident MIs and medication adherence, we project that full adherence 
may lead to annual savings of $98.2 million and $100.9 million over partial- and 
non-adherence, respectively. cOnclusiOns: Full adherence to statins and ACEI 
was associated with reduced per patient monthly direct medical costs of $109.7 and 
$134.4 over partial- and non-adherence. Using unweighted, rather than weighted, 
averages overestimated the economic impact, indicating the importance of data 
type in such analyses. Full adherence to guideline-recommended therapies has 
tremendous cost-saving implications.
MA3
THE EffECT Of COST-RElATED MEDICATION NONADHERENCE ON THE 
DECISION Of TAkINg Up MEDICARE pART D AMONg ElDERly MEDICARE 
BENEfICIARIES
Han Y., Balkrishna R.
University of Michigan, Ann Arbor, MI, USA
bAcKGROund: The sizable fraction of the elderly adults who are left without Part D 
coverage indicates there are potential barriers in taking up Part D, including infor-
mation barriers and economical barriers. Few studies have examined how cost-
related medication nonadherence (CRN) affected the willingness of taking up Part D 
among elderly adults using national representative data. Objectives: To estimate 
the impact of self-reported CRN on the decision of taking up Medicare Part D among 
Medicare beneficiaries age 65 and above who did not have Part D coverage in 2006 
incorporating the effect of complex sample survey design. MethOds: This retro-
spective cross-sectional study used data from the 2006 Health and Retirement Study 
database (2006 HRS). Information on patient demographics, social and economic 
factors and health insurance coverage were obtained by survey. The dual-eligible 
beneficiaries were excluded due to automatically enrollment. A total of 5,826 eligible 
risk of TM by hormone receptor status adjusting for age. Results: Among the 
86255 women with invasive breast cancer, 38621 (45%) underwent TM, 10261 (12%) 
were Her2 positive, and 9512 (11%) were Black. For Black women with T1 tumors, 
after adjusting for age, the odds of TM were 1.3 (95% CI 1.1, 1.6) times higher for 
estrogen receptor (ER)(+) and Her2(+) tumors compared to women who were ER(+)
Her2(-), 1.4 (95% CI 1.1, 1.8) times higher for ER(+)Her2(+) compared to ER(-)Her2(-), 
and 1.4 (95% CI 1.0, 1.8) times higher for ER(-)Her2(+) compared to ER(-)Her2(-). For 
White women with T1 tumors, after adjusting for age, the odds of TM were 1.4 (95% 
CI 1.3, 1.5) times higher for ER(+)Her2(+) compared to ER(+)Her2(-), 1.1 (95% CI 1.0, 
1.2) times higher for ER(+) Her2(+) compared to ER(-)Her2(-), and 1.7 (95% CI 1.5, 1.9) 
times higher for ER(-)Her2(+) compared to ER(-)Her2(-). Similar Results were seen 
for stage T2 tumors. cOnclusiOns: For both Black and White women with early 
stage tumors, Her2 positivity predicts TM. Further research should investigate the 
role of Her2 positivity in influencing the surgical decision-making of early stage 
breast cancer patients.
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A REvIEw Of THE lITERATURE REgARDINg BIOSIMIlARS: wHAT IS THE 
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Objectives: Although European Medicines Association approved 21 biosimilars 
from 2007-2014; the Food and Drug Administration approved its first, filgrastim, 
in 2014. Regulatory approvals require pharmacokinetic/pharmacodynamic stud-
ies and efficacy/safety trials with fewer patients and shorter durations than for 
reference biologicals. Cost savings are 20%-30%. However, uptake of biosimilars 
may be delayed since clinicians and decision makers may have concerns about 
clinically-relevant differences in effectiveness, safety, and/or immunogenicity. 
Therefore, our objective was to review published literature regarding studies 
of effectiveness, safety, immunogenicity, and costs of biosimilars versus refer-
ence biologicals. MethOds: We searched electronic databases using the term 
“biosimilar pharmaceuticals” as a major topic, with filters for English language 
and human species. Our inclusion criteria were: study design for comparison of 
biosimilars and data included in Results. We excluded editorials, in vitro stud-
ies, and descriptive summaries. Results: We identified 174 articles. Inclusion/
exclusion criteria left 19 equivalence studies for the following: epoetins (n= 4, 
21.1%), filgrastims (n= 10, 52.6%), monoclonal antibodies (MABs) (n= 2, 10.5%), 
tumor necrosis factor blockers and MABs (n= 1, 5.3%), and interferon (n= 2, 10.5%). 
The median sample size was 104, but there were 3 large studies (n= 6177, n= 904, 
n= 606). Fifteen studies (79.0%) reported comparative effectiveness. Most studies 
also reported on safety (n= 12, 63.2%), immunogenicity (n= 6, 33.6%), and/or costs 
(n= 3, 15.8%). Cost studies included a budget impact model regarding potential sav-
ings from adopting biosimilars versus reference biologics for rheumatic disease, 
a model of cost savings comparing biosimilar versus reference epoetins, and a 
survey of uptake and associated cost savings from various biosimilar filgrastims 
across European Union countries. cOnclusiOns: Most current published data 
on biosimilar equivalence focus primarily on effectiveness, evaluate relatively 
small numbers of patients, and report minimal data on safety, immunogenicity, or 
cost savings. To increase uptake, biosimilar manufacturers and regulators should 
consider conducting post-marketing surveillance research to provide additional 
data on safety, immunogenicity and costs.
HM4
HOw MUCH EvIDENCE DO wE NEED BEfORE IMplEMENTINg 
pHARMACOgENOMIC TESTINg IN THE ClINIC?
Guzauskas G.F., Serbin M., Veenstra D.L.
University of Washington, Seattle, WA, USA
Objectives: Consensus on the evidence required to recommend clinical pharma-
cogenomic testing is unclear. A formal assessment of pharmacogenomic evidence 
levels in relation to other clinical interventions, such as avoiding drug-drug inter-
actions (DDI), may be helpful for policymakers. The objective of this study was 
to quantitatively compare the evidence levels of two contested drug-attenuating 
interactions with clopidogrel antiplatelet therapy, and assess the value of obtain-
ing additional evidence to inform clinical practice guidelines. MethOds: We 
developed analogous value of information (VOI) decision models for: (1) avoidance 
of proton pump inhibitors (PPIs) in clopidogrel patients, and (2) pharmacogenomic-
guided antiplatelet selection, both versus no intervention. Interaction-specific 
parameters and model structures were the only dissimilarities. We calculated 
the expected value of obtaining perfect information (EVPI) per patient, and the 
expected population value of obtaining additional information through future 
studies (EVSI). Results: Current evidence for interaction-1 was slightly less 
uncertain (a 20% probability of making a non-optimal recommendation) than for 
interaction-2 (23%). The relative risk for cardiovascular death (conferred by con-
comitant PPI use in interaction-1, and reduced-function CYP2C19 alleles in interac-
tion-2) was the greatest source of uncertainty in both models. The expected value 
of perfect information for interaction-1 was $139 per patient, compared to $242 per 
patient for interaction-2. In simulated 10,000-patient clinical trials, the expected 
population value of future research for interaction-1 was $2 million, versus $110 
million for interaction-2. cOnclusiOns: The evidence levels for clopidogrel DDI 
and pharmacogenomic effects appear to be fairly similar. However, the value of 
conducting future research on clopidogrel pharmacogenomics is higher because 
of greater uncertainty about the impact of pharmacogenomic testing on cardio-
vascular mortality. Our findings imply that evidence-based clinical guidelines 
for DDI and pharmacogenomic effects should be generally similar with regard to 
direction and strength of recommendation. This contrasts to some degree with 
current guidelines and drug labeling.
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benefit for diabetes patients who do not require insulin. Under the Ontario Public 
Drug Programs (OPDP), these patients have a 200-400 strip/year limit, whereas 
patients who require insulin can receive up to 3,000 strips annually. The policy 
intent was not to change BGTS utilization for insulin patients; however, concerns 
exist around potential negative impacts on diabetes management. The objective of 
this analysis is to quantify the impact of this new BGTS utilization policy in Ontario 
across diabetes patients based on their diabetes treatment. MethOds: All patients 
who received BGTS coverage from the OPDP during July 2012 – September 2014 were 
selected for analysis using the IMS Brogan OPDP Database. Annual BGTS utiliza-
tion prior to the policy change (July 2012 – June 2013) was then compared to annual 
BGTS utilization following Ontario’s coverage limit (October 2013 - September 2014). 
Patients were categorized into one of four cohorts based on their diabetes medica-
tion history: ‘insulin only’,’ insulin + oral anti-diabetic (OAD)’, ‘OAD’, or ‘neither’. 
Changes in utilization patterns were assessed for each cohort. Results: 422,525 
patients were identified for the pre-period, and 422,154 patients were identified 
for the post-period. Overall BGTS unit volume declined from 192M to 147M (-24%) 
following the OPDP policy change. On average, the number of BGTS per patient 
per year decreased for ‘OAD ’ and ‘neither’ cohorts by 42% and 54%, respectively. 
Impact to patients managing diabetes with insulin was minimal: ‘insulin only’ (-1%) 
and ‘insulin + OAD’ (-2%). cOnclusiOns: BGTS utilization markedly decreased in 
diabetes patients not managed with insulin; test strip utilization was marginally 
impacted for patients using insulin.
MD3
ECONOMIC IMpACT Of CHANgES IN NICU vENTIlATION STRATEgIES wITH 
THE ADvENT Of NEw NONINvASIvE vENTIlATION TECHNIqUES: A REvIEw 
AND pROpOSED ASSESSMENT fRAMEwORk fOR HIgH flOw THERApy (HfT) AS 
A ROUTINE RESpIRATORy SUppORT pARADIgM
Pietzsch J.B.1, Garner A.M.1, McQueen M.C.2
1Wing Tech Inc., Menlo Park, CA, USA, 2Banner Thunderbird Medical Center, Glendale, AZ, USA
Objectives: High flow therapy (HFT) has been demonstrated to be a safe and effec-
tive noninvasive respiratory support technique for the treatment of pre-term infants 
in neonatal intensive care units (NICU). Our objective was to develop a quantita-
tive framework based on available evidence to estimate the economic impact of 
adoption of a HFT respiratory support strategy compared to current standard of 
care. MethOds: We constructed a model to estimate total cost per NICU episode 
of care by treatment strategy, considering utilization and duration of the differ-
ent types of ventilatory support modalities – conventional mechanical ventilation 
(CMV), nasal continuous positive airway pressure (nCPAP) ventilation, and HFT – as 
well as utilization levels of surfactant, chest x-rays, blood gas analyses and total 
NICU length of stay. Model parameters were derived from a recent study comparing 
respiratory modality utilization between five US-based neonatal intensive care units 
(NICUs) adopting a HFT strategy and a larger pool of NICUs in the Vermont-Oxford 
Network (VON), and from single center experience. We computed the total cost dif-
ference between the respiratory support strategies based on published cost data. 
Parameter uncertainty was tested in sensitivity analyses. Results: The base case 
analysis resulted in total average length of ventilation of 25.48 days for the non-HFT 
strategy (8.92 days nCPAP, 6.10 days HFT, 10.47 days CMV) and of 25.06 days (2.88 
days nCPAP, 16.86 days HFT, 5.32 days CMV) for the HFT strategy. HFT was associ-
ated with total projected cost savings of $2,317. Results were sensitive to length of 
HFT use, length of CMV, cost of HFT, and length of nCPAP support. cOnclusiOns: 
Adoption of a HFT strategy appears to be associated with meaningful savings in 
total NICU episode of care costs, primarily resulting from reductions in the time of 
conventional mechanical ventilation. Further research is warranted to substanti-
ate these findings.
MD4
ECONOMIC vAlUE Of IMpROvED ACCURACy fOR SElf-MONITORINg Of BlOOD 
glUCOSE DEvICES fOR TypE 1 DIABETES
McQueen RB1, Breton M.2, Ott M.3, Koa H.4, Beamer B.4, Campbell J.D.1
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Objectives: To simulate and compare clinical and economic outcomes of self-
monitoring of blood glucose (SMBG) devices along accuracy ranges and strip 
price. MethOds: We programmed a long-term type 1 diabetes natural history 
and treatment cost-effectiveness model. In phase one, using In Silico modeling 
validated by the Food and Drug Administration, we associated changes in accu-
racy error rates of SMBG devices to changes in HbA1c (holding hypoglycemic rates 
unchanged) and changes in severe hypoglycemia rates requiring an inpatient stay 
(holding HbA1c levels unchanged). In phase two, using Markov cohort simulation 
modeling, we estimated lifetime clinical and economic outcomes from the Canadian 
payer perspective. The primary comparison was a SMBG device with strip price 
$0.73 Canadian dollars (CAD) with accuracy error rate of 10% versus a SMBG device 
with strip price $0.60 CAD with accuracy error rate of 15%. Outcomes for the aver-
age patient, discounted at 3% per annum, were quality-adjusted life years (QALYs), 
costs, incremental cost-effectiveness ratios (ICERs), and budget impact. Results: 
Assuming the benefits translate into HbA1c improvements only, the ICER with accu-
racy error rate of 10% versus 15% was $11,500 CAD per QALY. Assuming the benefits 
translate into reduced severe hypoglycemic events that required an inpatient stay 
only, an SMBG device with accuracy error rate of 10% dominates (i.e., less costly, 
more effective) an SMBG device with accuracy error rate of 15%. Assuming SMBG 
errors only impact HbA1c improvements, and when varying all inputs simultane-
ously through a probabilistic sensitivity analysis, 91% of simulations were cost-
effective at a willingness-to-pay of $100,000 per QALY. The five-year budget impact 
findings ranged from $0.0005 per member per month for HbA1c improvements to 
cost-savings for severe hypoglycemic event reductions. cOnclusiOns: From the 
efficiency (cost-effectiveness) and affordability (budget impact) payer perspectives, 
reducing the error in SMBG devices appears to be an efficient and affordable strategy.
cases were recruited in our study. Results: The majority of the eligible Medicare 
beneficiaries responded “not at all likely” to take Part D (62%), and significant propor-
tions also reported “not too likely” to take Part D (21.46%), while few of them reported 
“somewhat likely”(9.44%) and “Very likely”(6.31%). Results of weighted cumulative 
logit regression indicated that people who had cost barriers in medication use 
were significantly more likely to take up Medicare Part D (OR= 2.62, 95% CI[2.00, 
3.44], p< 0.001). Males and older adults were less likely to take up Medicare Part D 
(OR= 0.83, 95% CI[0.74, 0.94] and OR= 0.98, 95% CI[0.97, 1.00], p< 0.01). cOnclusiOns: 
Results of this study indicated experiencing CRD was significantly associated with 
the probability of taking up Part D. CRN could be a motivation of taking up Part D. 
Thus, characteristics of beneficiaries who reported having CRN, especially those 
who continued to experience CRN after taking up Part D, need further studies.
MA4
COMpREHENSIvE ASSESSMENT Of pATIENT ADHERENCE TO DRUg THERApy: 
AN ExAMplE UTIlIzINg REAl wORlD DATA fOR AN ORAl MUlTIplE 
SClEROSIS TREATMENT
Irwin D.E.1, Cappell K.A.2, Davis B.M.2, Wu Y.3, Grinspan A.4, Gandhi S.K.3
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Objectives: Medication possession ratio (MPR) and persistence are typically 
used as measures of patients’ drug use patterns. However, these measures may 
not capture all aspects related to real world dosing. We aim to explore additional 
approaches to enhance meaningful interpretation of patients’ drug use patterns 
using persistence, adherence and average daily dose (ADD) data of dimethyl fuma-
rate (DF) in a real world dataset. MethOds: A retrospective cohort study using the 
MarketScan Commercial and Medicare Databases (March 2013 – January 2014) was 
conducted in adult multiple sclerosis patients. Patients with DF claims who were 
continuously enrolled for at least 9 months before and after starting therapy were 
included (n= 2,879). Outcomes included time to treatment non-persistence (switch 
to another disease modifying therapy (DMT) or drug discontinuation of ≥ 30 days), 
adherence (MPR and percent of days covered (PDC)), and estimated ADD. Data were 
interpreted in the context of the FDA approved daily dosing (240 mg b.i.d.), and an 
earlier trial (1) reporting dose-related MRI findings indicating non-significant effects 
on brain lesions for 360 mg/day and 120 mg/day doses. Results: The mean (SD) 
DF treatment duration was 96 (66) days (median 83) and 24% of patients became 
non-persistent. Mean (SD) MPR and PDC were 0.83 (0.26) and 0.75 (0.29), respectively. 
ADD (SD) was 417 mg/day (221) with 15.3% treated at < 240 mg/day, 5.6% at 240-359 
mg/day, 47.8% at 360-479 mg/day, and 31.3% at ≥ 480 mg/day (i.e., 20.9% treated at 
< 360 mg/day and 68.7% treated at less than the labeled dose). cOnclusiOns: The 
finding of a large proportion of patients receiving potentially sub-optimal treatment, 
as determined by ADD on DF, indicates significant potential clinical consequences 
for these patients. The approach used in this study could be used in other similar 
studies examining treatment adherence to enhance meaningful interpretation of 
adherence data. 1. Lancet 2008; 372(9618):1463-72.
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MD1
ECONOMIC EvAlUATION Of BST-CARgEl AS AN ADjUNCT TO MICROfRACTURE 
vERSUS MICROfRACTURE AlONE IN kNEE CARTIlAgE SURgERy
Frappier J.
Data 4 Actions, Blainville, QC, Canada
Objectives: Knee cartilage damage is a common cause of referral for ortho-
paedic surgery. Treatment aims to reduce pain and symptoms by repairing car-
tilage. Microfracture, the current standard of care, yields good short-term clinical 
outcomes; however, treatment might fail after 2-3 years. A Chitosan-Beta glyc-
erolphosphate bioscaffold is used as an adjunct to microfracture and demonstrates 
improvements in quantity and quality of repaired tissue, potentially reducing the 
risk of treatment failure. This study aimed to establish the economic value of 
bioscaffold versus microfracture alone in knee cartilage repair from the societal 
perspective, using Germany as the reference market. MethOds: A decision tree 
with a 20-year time-horizon was constructed, in which undesirable clinical events 
were inferred following initial surgery. These events consisted of pain management, 
surgery and total knee replacement. Clinical outcomes were taken from the pivotal 
clinical trial, supplemented by other literature. Data and assumptions were vali-
dated by an internationally recognized Delphi panel. All relevant resource use and 
costs for procedures and events were considered. Results: In a group of patients 
with all lesion sizes, the model inferred that bioscaffold yields a positive return on 
investment at year 4 (with 20-year cumulative cost savings of € 6,448). Reducing 
the incremental risk of treatment failure gap between bioscaffold and microfrac-
ture by 25% to 50% does not alter this conclusion. Cost savings are greatest for 
patients with large lesions; Results for patients with small lesions are more mod-
est. cOnclusiOns: The Chitosan-Beta glycerolphosphate bioscaffold potentially 
represents a cost-saving alternative for patients with knee cartilage injury by reduc-
ing the risk of clinical events through regeneration of chondral tissue with hyaline 
characteristics. Since the burden of this condition is high, both to the patient and 
society, an effective and economically viable alternative is of importance.
MD2
COvERAgE lIMITS ON BlOOD glUCOSE TEST STRIp REIMBURSEMENT fOR 
DIABETICS IN CANADA: UTIlIzATION IMpACT fOR DIABETIC pATIENTS IN THE 
ONTARIO pUBlIC DRUg pROgRAM (OpDp)
Bosnic N.1, Goodfield J.M.2, Robertson C.M.2, Zhang Y.1
1IMS Brogan, Kanata, ON, Canada, 2IMS Brogan, Mississauga, ON, Canada
Objectives: In August 2013 the Ontario government implemented annual limits 
on the number of blood glucose test strips (BGTS) it will reimburse for people with 
diabetes. The change is based on research that shows BGTS have a limited clinical 
